期刊文献+

米氮平和阿米替林治疗躯体形式障碍对照研究 被引量:2

Comparison of Mirtazapine and Amitriptyline in the Treatment of Somatoform Disorders
下载PDF
导出
摘要 目的探讨米氮平治疗躯体形式障碍的疗效及安全性。方法对80例躯体形式障碍患者分别用米氮平或阿米替林治疗8周。采用汉密尔顿抑郁量表(HAMD)及副反应量表(TESS)评定药物疗效及不良反应。结果米氮平与阿米替林疗效相当,起效快,米氮平不良反应轻微。结论米氮平治疗躯体形式障碍疗效肯定,不良反应小。 Objective To investigate the effectiveness and the safeness of mirtazapine and amitriptyline in the treatment of somatoform disorders. Methods Eighty patients with somatoform disorders were divided into two groups and were treat with mirtazapine and amitriptyline respectively for eight weeks. All patients were assessed with HAMD and TESS to estimate the efficacy and side effects of the drugs. Results Compared with amitriptyline, mirtazapine was shown to have almost the same effectiveness, but quicker response and milder side effects. Conclusion Mirtazapine has positive efficacy and less side effect in the treatment of somatoform disorder.
出处 《中国健康心理学杂志》 2006年第5期560-561,共2页 China Journal of Health Psychology
关键词 米氮平 阿米替林 躯体形式障碍 副反应量表 Mirtazapine Amitriptyline Somatoform disoder TESS
  • 相关文献

参考文献6

二级参考文献28

  • 1李一云,季建林.文拉法辛与米氮平治疗抑郁症的临床比较分析[J].上海精神医学,2003,15(6):358-360. 被引量:23
  • 2Auttila SAK, et al: CNS Drug Review, 2001; 7(3): 249-264.
  • 3Guelfi JD, et al: J Clin Psychopharmacol. 2001; 21: 425-431.
  • 4Zivkov M, et al: Hum Psychopharmacol. 1995; S135-S145.
  • 5Leinonen E, et al: Int Clin Psychopharmacol. 1999; 14:329-337.
  • 6Benkert O, et al: J Clin Psychiatry, 2000; 61 (9): 656-663.
  • 7David J, et al: J Clin Psychiatry, 1999; 60 (Suppl 17): 23 -27.
  • 8Schatzberg AF, et al: Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York, 911-920,1995.
  • 9Schittecatte M, et al: Arch Gen Psychiatry, 1992; 49: 637-642.
  • 10Derogatis LR, et al: JAMA. 1993; 249:751-757.

共引文献148

同被引文献12

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部